Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 2

Safety and tolerability of antipsychotics: focus on amisulpride

Authors Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira

Published 1 October 2010 Volume 2010:2 Pages 205—211

DOI https://dx.doi.org/10.2147/DHPS.S6226

Review by Single-blind

Peer reviewer comments 3

Mario F Juruena1, Eduardo Pondé de Sena2, Irismar Reis de Oliveira3
1Stress and Affective Disorders Programme, Department of Neuroscience and Behaviour, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil; 2Department of Pharmacology, Institute of Health Sciences, Federal University of Bahia, Salvador; 3Department of Neurosciences and Mental Health, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil

Abstract: The introduction of the atypical antipsychotic drugs represents an important advance in the treatment of schizophrenia, because the therapeutic efficacy, tolerability, and safety profiles of these agents seem to be superior to that of the classical neuroleptics. As would be predicted from the pharmacologic profile of a pure D2/D3 receptor blocker, amisulpride is an atypical antipsychotic agent, effective for positive and negative symptoms, which can bring about additional improvement in the social functioning and quality of life of patients with schizophrenia. Amisulpride is effective in acute schizophrenia as determined by Clinical Global Impression scores. The major concern regarding the safety of the atypical antipsychotics is related to their propensity to induce weight gain and alter glucose and lipid metabolism. Amisulpride has one of the lowest potentials for weight gain of all the antipsychotic agents, and is associated with clearly lower use of antiparkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics. Amisulpride is well tolerated with regard to anxiety and insomnia, and not notably different from placebo. Amisulpride has a pronounced prolactin-elevating effect which appears to be independent of dosage and duration of administration. Hyperprolactinemia rapidly reverses following amisulpride discontinuation. Amisulpride benefits patients with negative symptoms, and is the only antipsychotic to demonstrate efficacy in patients with predominantly negative symptoms. Amisulpride maintains its efficacy when used for medium/long-term treatment, as demonstrated in studies of up to 12 months. In terms of relevance of the effects, superiority is observed for quality of life, social adaptation, and functioning, as measured by the Quality of Life and Functional Status Questionnaire scales. In conclusion, amisulpride is an antipsychotic agent with proven efficacy and good tolerability. Moreover, this drug can help people with schizophrenia to attain social reinsertion.
Keywords: amisulpride, antipsychotic agents, safety, adverse events, tolerability
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Readers of this article also read:

Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine

Ogedengbe OS, Ezeani IU, Chukwuonye II, Anyabolu EN, Ozor II, Eregie A

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015, 8:437-445

Published Date: 15 September 2015

Papilledema: epidemiology, etiology, and clinical management

Rigi M, Almarzouqi SJ, Morgan ML, Lee AG

Eye and Brain 2015, 7:47-57

Published Date: 17 August 2015

The prevalence of obstructive sleep apnea-hypopnea syndrome-related symptoms and their relation to airflow limitation in an elderly population receiving home care

Kleisiaris CF, Kritsotakis EI, Daniil Z, Tzanakis N, Papaioannou A, Gourgoulianis KI

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1111-1117

Published Date: 10 October 2014

A study to assess the feasibility of undertaking a randomized controlled trial of adherence with eye drops in glaucoma patients

Richardson C, Brunton L, Olleveant N, Henson DB, Pilling M, Mottershead J, Fenerty CH, Spencer AF, Waterman H

Patient Preference and Adherence 2013, 7:1025-1039

Published Date: 7 October 2013

Antipsychotic agents: efficacy and safety in schizophrenia

de Araújo AN, de Sena EP, de Oliveira IR, Juruena MF

Drug, Healthcare and Patient Safety 2012, 4:173-180

Published Date: 29 November 2012

Genetics of rheumatoid arthritis: GWAS and beyond

McAllister KM, Eyre S, Orozco G

Open Access Rheumatology: Research and Reviews 2011, 3:31-46

Published Date: 3 June 2011

Temporal variation of out-of-hospital cardiac arrests in an equatorial climate

Marcus EH Ong, Faith SP Ng, Susan Yap, et al

Open Access Emergency Medicine 2010, 2:37-43

Published Date: 15 April 2010